A population-based study of thrombolysis for acute stroke in South Australia

Medical Journal of Australia

Volumn 194, Issue 3, 2011, Pages 111-115

  Leyden, James M ^a   Chong, Woon K ^a   Kleinig, Tim ^b   Lee, Andrew ^c   Field, John B ^d   Jannes, Jim ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

AGED; ARTICLE; AUSTRALIA; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; FEMALE; HEALTH CARE ACCESS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; POPULATION RESEARCH; REGISTER; RETROSPECTIVE STUDY; RURAL AREA; STROKE UNIT; URBAN AREA;

EID: 79951895605     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2011.tb04191.x     Document Type: Article

References (18)

1. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004; 363: 768-774.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-1329.
3. Kaste M, Thomassen L, Grond M, et al. Thrombolysis for acute ischemic stroke: a consensus statement of the 3rd Karolinska Stroke Update, October 30-31, 2000. Stroke 2001; 32: 2717-2718.
4. Wardlaw JM, Murray V, Berge E, Del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2009; (4): CD000213.
5. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372: 1303-1309.
6. Leung TW, Wong KS. Thrombolysis with alteplase for acute ischemic stroke: safe and effective outside the 3-hour time window? Nat Clin Pract Neurol 2009; 5: 70-71.
7. Sudlow C, Warlow C. Getting the priorities right for stroke care. BMJ 2009; 338: b2083.
8. Sudlow CL, Warlow CP. Comparing stroke incidence worldwide: what makes studies comparable? Stroke 1996; 27: 550-558.
9. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
10. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280-2284. (Pubitemid 29517722)
11. National Stroke Foundation. Clinical guidelines for acute stroke management. Melbourne: NSF, 2007.
12. Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2010; 3: 291-302.
13. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
14. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-1458.
15. Kleinig TJ, Kimber TE, Thompson PD. Stroke prevention and stroke thrombolysis: quantifying the potential benefits of best practice therapies. Med J Aust 2009; 190: 678-682.
16. Kleindorfer D, Xu Y, Moomaw CJ, et al. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Stroke 2009; 40: 3580-3584.
17. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2003; 2: 43-53. (Pubitemid 37443343)
18. Ad Hoc Committee representing the National Stroke Foundation and the Stroke Society of Australasia. The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke - a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia. Intern Med J 2009; 39: 317-324.